Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
PRQR
vs
S&P 500
PRQR
S&P 500
Over the past 12 months, PRQR has underperformed S&P 500, delivering a return of -53% compared to S&P 500's +13% growth.
Stocks Performance
PRQR vs S&P 500
Performance Gap
PRQR vs S&P 500
Performance By Year
PRQR vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
ProQR Therapeutics NV
Glance View
ProQR Therapeutics is a biotech company that designs RNA-based medicines for people with rare genetic diseases. Instead of making traditional small-molecule drugs or antibodies, it works on therapies that try to correct problems caused by faulty genes at the RNA level, which is the step between DNA and protein production. Its main work is in developing treatments that can help cells make the right protein again. The company does not sell a broad range of commercial drugs. It mainly earns money by advancing its own drug candidates through research and clinical development, and in some cases by working with partners or licensing its technology. Its customers are not everyday patients in the usual sense; its business is aimed at doctors, hospitals, and ultimately patients with serious inherited conditions, while its funding typically comes from investors and collaboration agreements that support drug development. What makes ProQR different is its focus on a very specific part of the drug-making chain: RNA editing and RNA-targeted medicines for rare diseases. That puts it in a high-risk, high-science corner of biotech, where value depends on turning laboratory results into treatments that can reach approved, prescription medicine status. In plain terms, ProQR is trying to turn gene-level biology into practical therapies for diseases with few good treatment options.
